豚インフルエンザワクチンの世界市場規模：製品タイプ別、用途別、地域範囲別、予測

豚インフルエンザワクチンの市場規模と予測

豚インフルエンザワクチンの市場規模は、ここ数年、大幅な成長率で速いペースで成長しており、予測期間中（すなわち2026年から2032年）に大きく成長すると予測されています。

• 豚インフルエンザは、豚フルーとも呼ばれ、豚を罹患させるインフルエンザウイルスによって引き起こされる呼吸器疾患です。この病気はヒトにも感染する可能性があり、ヒト豚インフルエンザの発生につながります。
• 豚インフルエンザの世界市場には、ワクチンや治療薬の開発、製造、流通が含まれます。
• 豚インフルエンザワクチンと治療薬の用途は、主に豚とヒトの病気の予防と治療に重点を置いています。豚の場合、ワクチン接種は病気の蔓延を防ぐために行われますが、これは農家にとって大きな経済的損失につながります。ヒトの場合、豚インフルエンザワクチンと治療が、呼吸器系疾患を引き起こし、重症化すると入院や死亡につながるこの病気の予防と治療に使用されます。
• 将来の展望として、豚インフルエンザ市場は、この病気に対する認識の高まりと、より効果的な新しいワクチンや治療法の開発によって成長すると予想されます。
• さらに、豚インフルエンザの蔓延を抑制し、将来の発生を予防するための政府の取り組みも、市場の成長を後押しすると予想されます。
• また、畜産業の成長を促進し、疾病予防対策の必要性を高めている動物性タンパク質製品に対する需要の増加も、市場の恩恵をもたらすと期待されています。

豚インフルエンザワクチンの世界市場力学

豚インフルエンザワクチンの世界市場を形成している主な市場力学は以下の通り：

主な市場促進要因

• 豚インフルエンザ患者の増加：豚インフルエンザ感染者の増加：世界の豚インフルエンザ感染者の増加は、市場の成長を促進する主な要因です。これが豚インフルエンザワクチンの需要増につながり、市場成長に寄与しています。
• 予防接種プログラムに対する政府の取り組み：豚インフルエンザに対するワクチン接種の重要性に関する人々の意識の高まり。世界中の政府が予防接種プログラムを推進するためのイニシアチブを取っていることが、市場の成長を後押しする結果となりました。
• ワクチン生産と流通の進歩：ワクチン製造業者は、より効率的にワクチンを製造し、より多くの人々にワクチンを配布することができるようになったため、技術導入の増加が市場を牽引します。
• 予防ヘルスケアに対する需要の高まり：予防医療の利点に対する意識の高まりが、豚インフルエンザワクチンを含むワクチン需要の増加につながっています。
• ヘルスケア支出の増加：世界のヘルスケア支出の増加に伴い、疾病予防への関心が高まっており、豚インフルエンザワクチンの需要を牽引すると予想されます。

主な課題

• 地域によってワクチンの入手可能性が限られていること：豚インフルエンザワクチンの需要が拡大しているにもかかわらず、これらのワクチンが容易に入手できない地域がまだ存在します。そのため、こうした地域での市場の可能性は限られています。
• ワクチンの高コスト：豚インフルエンザワクチンのコストは、特に低所得国の一部の人々にとって障壁となる可能性があります。このため、ワクチン需要が制限され、市場の成長が妨げられる可能性があります。
• ワクチンの有効性の限界：豚インフルエンザウイルスはすぐに変異するため、ワクチンの有効性が低下する可能性があります。ワクチン製造業者にとっては、進化するウイルス株に対応し続けることが課題となります。
• 厳しい規制：豚インフルエンザワクチン市場は規制が厳しいため、承認取得や規制要件への対応という点でメーカーに課題が生じる可能性があります。
• ワクチンへの抵抗感：副作用への懸念やヘルスケアシステムに対する信頼の欠如など、さまざまな理由から豚インフルエンザワクチンの接種をためらう人がいます。これはワクチン需要を制限し、市場の成長を妨げる可能性があります。

主要動向：

• 高まるワクチン接種への懸念：人獣共通感染症や豚インフルエンザのパンデミックに対する意識の高まりが、豚のワクチン接種需要の増加を促しています。
• 牛群の健康への注目：豚の生産者は、豚インフルエンザのワクチン接種が牛群の健康と生産ロスの防止に経済的利益をもたらすことを認識しつつあります。
• 厳しい規制措置：規制機関は動物用ワクチンのより厳格な品質管理措置を実施する一方、政府機関は豚の豚インフルエンザワクチン接種に関するガイドラインを発行する可能性があり、市場の成長に影響を与える可能性があります。

目次

第1章 豚インフルエンザワクチンの世界市場導入

• 市場イントロダクション
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 豚インフルエンザワクチンの世界市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 豚インフルエンザワクチンの世界市場：製品タイプ別

• 概要
• 生ワクチン
• 不活化ワクチン

第6章 豚インフルエンザワクチンの世界市場：用途別

• 概要
• 商品豚
• 繁殖豚

第7章 豚インフルエンザワクチンの世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第8章 豚インフルエンザワクチンの世界市場競合情勢

• 概要
• 各社の市場ランキング
• 主な開発戦略

第9章 企業プロファイル

• Chengdu TECBOND
• Green Cross Veterinary
• Hipra
• MSD Animal Health（Merck）
• Zoetis
• CAHIC
• Merial
• Ceva
• Ringpu Biology
• DHN

第10章 付録

• 関連調査

Swine Influenza Vaccines Market Size And Forecast

Swine Influenza Vaccines Market size is growing at a faster pace with substantial growth rates over the last few years and is estimated to grow significantly during the forecasted period i.e. 2026 to 2032.

• Swine influenza, also known as swine flu, is a respiratory disease caused by the influenza virus that affects pigs. The disease can also be transmitted to humans, leading to outbreaks of human swine influenza.
• The global swine influenza market includes the development, manufacturing, and distribution of vaccines and treatments for the disease.
• The application of swine influenza vaccines and treatments is primarily focused on preventing and treating the disease in pigs and humans. In the case of pigs, vaccination is used to prevent the spread of the disease, which can lead to significant economic losses for farmers. In humans, swine influenza vaccines and treatments are used to prevent and treat the disease, which can cause respiratory illness and, in severe cases, lead to hospitalization or death.
• In terms of future scope, the swine influenza market is expected to grow with increasing awareness about the disease and the development of new and more effective vaccines and treatments.
• Additionally, government initiatives to control the spread of swine influenza and prevent future outbreaks are expected to boost the growth of the market.
• The market is also expected to benefit from the increasing demand for animal protein products, which is driving the growth of the livestock industry and increasing the need for disease prevention measures.

Global Swine Influenza Vaccines Market Dynamics

The key market dynamics that are shaping the global Swine Influenza Vaccines Market include:

Key Market Drivers:

• Increasing Incidence of Swine Flu Cases: The rising prevalence of swine flu infections across the globe is a major factor driving the growth of the market. This has led to an increase in demand for swine flu vaccines, thereby contributing to the market growth.
• Government Initiatives towards Immunization Programs: Growing awareness among people regarding the importance of vaccination against swine influenza. Governments programs around the world are taking initiatives to promote immunization programs, resulted in a boost in the growth of the market.
• Advancements in Vaccine Production and Distribution: Rising adoption of technology will drive the market as vaccine manufacturers are now able to produce vaccines more efficiently and distribute them to a larger population.
• Growing Demand for Preventive Healthcare: Increasing awareness about the benefits of preventive healthcare is leading to a rise in demand for vaccines, including swine flu vaccines.
• Rising Healthcare Expenditure: With the increase in healthcare spending globally, there is a growing focus on disease prevention, which is expected to drive the demand for swine flu vaccines.

Key Challenges:

• Limited Availability of Vaccines in Distinct Regions: Despite the growing demand for swine flu vaccines, there are still some regions where these vaccines are not readily available. This limits the market potential in these areas.
• High Cost of Vaccines: The cost of swine flu vaccines can be a barrier for some individuals, especially in low-income countries. This can limit the demand for vaccines, thereby hindering the growth of the market.
• Limited Efficacy of Vaccines: Swine flu viruses can mutate quickly, which can reduce the efficacy of vaccines. This can be a challenge for vaccine manufacturers to keep up with the evolving strains of the virus.
• Stringent Regulations: The swine flu vaccine market is highly regulated, which can create challenges for manufacturers in terms of obtaining approvals and meeting regulatory requirements.
• Vaccine Hesitancy: Some individuals may be hesitant to receive swine flu vaccines due to various reasons, such as concerns about side effects or a lack of trust in the healthcare system. This can limit the demand for vaccines and hinder the growth of the market.

Key Trends:

• Growing Vaccination Concerns: The rising awareness of zoonotic diseases and the potential swine flu pandemics is driving increased demand for pig vaccination.
• Focus on Herd Well-being: Pig producers are increasingly recognizing the economic benefits of swine flu vaccination for herd health and preventing production losses.
• Stringent Regulatory Measures: Regulatory bodies are implementing stricter quality control measures for animal vaccines, while government agencies may issue guidelines for swine flu vaccination in pigs, potentially influencing market growth.

Global Swine Influenza Vaccines Market Regional Analysis

Here is a more detailed regional analysis of the global Swine Influenza Vaccines Market:

North America:

• The increasing demand for Swine Influenza Vaccines Market is significant in North America because of the region's demand for the product occasionally surges during flu seasons or in reaction to swine flu diseases. In general, the market is growing steadily due to factors like population expansion, immunization campaigns, and public health efforts.
• Witnessing a rise in the number of swine flu influenza cases in recent years. The government in Mexico has been taking various measures to improve the healthcare infrastructure in the country and increase access to vaccines, which has been driving the growth of the market in the region.
• Increasing awareness regarding the importance of vaccination is also expected to drive the market for swine influenza vaccines in North America. As people become more aware of the benefits of vaccination and the risks associated with not vaccinating, they are more likely to seek out vaccines, thereby contributing to the growth of the market.

Europe:

• The European Medicines Agency (EMA) and other regulatory agencies enforce strict guidelines for the approval and production of vaccines, which impacts market entrance obstacles and strategies for product differentiation.
• The main factors driving the demand for swine influenza vaccines include disease outbreaks, government programs encouraging livestock health, and growing swine producer awareness of the advantages of immunization.
• Furthermore, developments in vaccination technology and growing worries about the spread of zoonotic diseases are reflected in market patterns. Product innovation, price strategies, and industry-wide strategic alliances are characteristics of competitive dynamics. Overall, a comprehensive regional study reveals pathways forward and emphasizes the intricate interactions among variables influencing the European Swine Influenza Vaccines Market.

Asia Pacific:

• The Asia Pacific region is an important market for swine influenza vaccines due to the high incidence of the disease in the region. A regional analysis of the market can help identify the key market trends and drivers.
• Increasing demand for vaccine are expected to drive growth due to their large populations and increasing awareness about the importance of vaccination. On the supply side, many leading global players have established their manufacturing facilities in the region, which has helped to increase the availability of vaccines.
• Additionally, there may be cultural barriers to vaccine adoption in some regions, which will need to be addressed through targeted marketing and education campaigns.

Global Swine Influenza Vaccines Market: Segmentation Analysis

The Global Swine Influenza Vaccines Market is segmented on the basis of Product Type, Application, And Geography.

Swine Influenza Vaccines Market, By Product Type

• Live Vaccine
• Killed Vaccine

Based on Product Type, The market is segmented into Live Vaccine and Killed Vaccine. The Live vaccine is dominated throughout the forecast period. Due to Live vaccines exhibit superior efficacy in conferring cross-protection against emerging strains and variants, offering a strategic advantage in combating evolving disease threats within the swine industry. Despite concerns regarding potential reversion to virulence and strict storage and handling requirements, advancements in vaccine technology and stringent quality control measures have significantly mitigated these risks, bolstering confidence among stakeholders.

Swine Influenza Vaccines Market, By Application

• Commodity Pig
• Breeding Pig

Based on Application, The market is segmented into Commodity Pig and Breeding Pig. The commodity pig is dominate the market often raised for meat production purposes, represent a significant portion of the swine population in Europe. Given the large-scale nature of commodity pig production and the emphasis on maximizing efficiency and productivity, disease prevention measures, including vaccination, are crucial for maintaining herd health and minimizing economic losses associated with disease outbreaks. Swine influenza vaccines play a vital role in protecting commodity pig herds from respiratory diseases, ensuring optimal growth rates and meat quality.

Key Players

The "Global Swine Influenza Vaccines Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Chengdu TECBOND,Green Cross Veterinary, Hipra, MSD Animal Health (Merck), Zoetis, CAHIC, Merial, Ceva, Ringpu Biology, and DHN.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis.

• Swine Influenza Vaccines Market: Recent Developments
• In August 2023, Boehringer ingelheim introduced new influenza vaccine for swine. They developed and sold by Boehringer Ingelheim, Ingelvac Provenza is the first live attenuated influenza vaccine for growing pigs and provides protection against the threat of influenza virus strains H1N2 and H3N21.
• In June, 2023, Husker scientist has developed a robust vaccine against a strain of swine influenza. Framed by a model of nucleic acid proteins. They developed more efficient and long-lasting vaccination strategies in vulnerable pig population.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL SWINE INFLUENZA VACCINES MARKET

• 1.1 Introduction of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL SWINE INFLUENZA VACCINES MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL SWINE INFLUENZA VACCINES MARKET, BY PRODUCT TYPE

• 5.1 Overview
• 5.2 Live Vaccines
• 5.3 Killed Vaccines

6 GLOBAL SWINE INFLUENZA VACCINES MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Commodity Pig
• 6.3 Breeding Pig

7 GLOBAL SWINE INFLUENZA VACCINES MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East & Africa

8 GLOBAL SWINE INFLUENZA VACCINES MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 Chengdu TECBOND
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Green Cross Veterinary
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Hipra
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 MSD Animal Health (Merck)
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 Zoetis
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 CAHIC
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments
• 9.7 Merial
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments
• 9.8 Ceva
  • 9.8.1 Overview
  • 9.8.2 Financial Performance
  • 9.8.3 Product Outlook
  • 9.8.4 Key Developments
• 9.9 Ringpu Biology
  • 9.9.1 Overview
  • 9.9.2 Financial Performance
  • 9.9.3 Product Outlook
  • 9.9.4 Key Developments
• 9.10 DHN
  • 9.10.1 Overview
  • 9.10.2 Financial Performance
  • 9.10.3 Product Outlook
  • 9.10.4 Key Developments

10 Appendix

• 10.1 Related Research